<h4>Background</h4>This study investigated whether triple therapy with human chorionic gonadotropin (hCG), follicle-stimulating hormone(FSH) and testosterone(T) in congenital hypogonadotropic hypogonadism(CHH) promoted more timely virilization, aiding psychosocial development while reducing hCG requirements, offering a balanced approach to long-term management.<h4>Methods</h4>An open-label randomized controlled trial (1:1:1) was conducted in adult males with CHH. The gene discussed is BRD2; the disease is cartilage-hair hypoplasia.